Steven J. Potts, Ph.D., MBA

Executive Summary: Steve has worked in oncology since 1999 and has experience in a wide range of areas across drug development and diagnostics, including medical affairs, product development, sales, marketing, and general management. He founded the multi-armed immunotherapy company, OncoMyx, in 2018 and raised $75M total of venture funding. Previously, he was Vice President of Medical Affairs at Ignyta, which was acquired by Roche/Genentech in 2017, and he led the global operation of the testing of over 20,000 patients in an oncology basket trial for entrectinib in 15 countries. The ROS1 & TRK kinase inhibitor, now launched by Roche (www.rozlytrek.com), was the first in the industry to receive simultaneous breakthrough designation equivalents in USA, Europe, and Japan, and also one of the first to run a global concurrent registrational adult and pediatric trial.

WORK EXPERIENCE

International Cancer Advocacy Network. Chair, Drug Development Council (Volunteer). 2021-present. **https://askican.org/.** ICAN® is a 501(c)(3) patient advocacy and research advocacy organization with a small staff of professional advocates assisted by hundreds volunteers worldwide. With volunteer leadership representing 17 different time zones, ICAN works literally around the clock, focusing on Personalized Medicine Cancer Case Navigation Programs, health information technology issues, legislative initiatives, and research projects.

OncoMyx Therapeutics Founding CEO, Board Member. June 2018 – July 2022. www.oncomyx.com
Founded and raised $75M for OncoMyx, a startup oncolytic virus therapeutic company. OncoMyx is based on breakthrough research at Arizona State University for therapeutic IV delivery in solid and heme tumors with a multi-armed myxoma virus.

- Founded company as a university spin-out, created strong intellectual property portfolio, recruited management team (CSO, CBO/CFO, VP Operations, VP People), and raised initial $25 million Series A (July 2019). Built company to 25 employees.
- Advanced first multi-armed oncolytic virus through development candidate selection and into CMC and IND preparatory work
- Raised $50M Series B (Nov 2021) to support further IND and CMC work and early clinical programs
- 10 scientific posters and presentations at oncology conferences (AACR, Society for Immunotherapy of Cancer, International Oncolytic Virus Conference)
- Created strong Board of Directors and Scientific Advisory Board
- Recommended to BoD to shut down company and return majority of Series B funds to investors after non-competitive preclinical data package

Ignyta Pharmaceuticals Vice President, Global Medical & Diagnostic Affairs San Diego, CA. June 2015 – May 2018 . www.rozlytrek.com Acquired by Roche/Genentech in 2018.
STARTRK-2 trial is a registration-enabling basket trial of the small molecule entrectinib to support two NDA filings: ROS1 NSCLC and a tumor agnostic TRK registration. Entrectinib was the first molecule to achieve simultaneous Break Through Designation equivalents in USA, Europe, and Japan.

In collaboration with clinical the above work resulted in over 20,000 patients screened in two years, and meeting clinical trial enrollment goals in a TRK patient population that was almost unknown in 2015 and rare (less than 1 in 150 patients across 30+ histologies**).**

Flagship Biosciences Chief Executive Officer and Founder, Chairman, Board Member. Westminster, CO. 2010- June 2015 www.flagshipbio.com. Created the first digital pathology services company.

- Wrote business plan, raised capital, and bootstrapped company which grew to 75 employees. Debt-free and cash flow positive with continued rapid growth trajectory. 5 years of consecutive 100% annual growth. Deals with 40 plus pharma and biotech companies.
- Over 400 quantitative pathology studies in Phase One, Two and Three clinical trials (CLIA/CAP compliant).
- Flagship's novel quantitative tissue analysis platform was a secondary endpoint in the approval of Exondys (eteplirsen) in muscular dystrophy (quantitative image analysis of muscle biopsies). Negotiated vendor deal with Sarepta.
- Filed and successfully received two 510k IDEs for image analysis in breast cancer IHC under contract with partners Philips and Olympus.
- Sold to private family equity firms for 8x return for shareholders over 2.5 year holding period

Aperio Technologies. General Manager 2006-2010. Created the industry's most dominant digital pathology platform (now Leica/Danaher). Multiple Positions leading to General Manager, Pharmaceutical Sector. San Diego. 2006-2010. (acquired by Danaher). Promoted from Director of Marketing to Director of Sales to General Manager (General Management Responsibility) over a four year period. Managed all aspects of the pharmaceutical sector business, including managing teams from product development, marketing, and sales. Negotiated and executed deal terms with nearly all of the top 15 pharma companies.

Quest Diagnostics. Group Leader of Biostatistics & Bioinformatics. 2004-2006.
Reporting to the Chief Information Officer, responsible for identifying and implementing new technology at Quest Diagnostics, that crosses IT and Science lines. Worked in collaboration with marketing, new product development R&D, IT, and Compliance to both build and buy new technologies that are critical for launching new diagnostic tests. Hired and trained two Stanford Ph.D. bioinformaticians/biostatisticians to serve the needs of Nichols Institute. Created what was to become the Bioinformatics Department at Quest Diagnostics (now a 100+ person department in rare disease and oncology).

Accelrys (now Biovia). **Product Manager**, Drug Development Software. Marketing. Bioinformatics. San Diego, CA. 2002 – 2004.
Marketing management in a $120 million annual revenue portfolio of bioinformatics enterprise software used by pharmaceutical and biotech companies in compound registry, ADME, crystallography and computational medicinal chemistry. Part of team that produced the first Windows version of what is now Biovia's Discovery Studio – now widely used across the industry in medicinal and computational chemistry and drug discovery.

SurroMed (acquired by PPD). Bioinformatics Pharmaceutical Scientist. 2000-2002. Developed software and data mining for biomarker studies using high throughput flow cytometry on GSK partnered drug products.

EDUCATION

Ph.D. Biological Engineering. University of California, Davis. 1999.
M.B.A. University of California, Davis. 1998.
M.S. Biological Engineering. University of California, Davis. 1996.
B.S. Physics. Wheaton College. Wheaton, Illinois. 1994. Minor in Spanish/Anthropology. 6 month Internship in Honduras.

PATENTS AND PUBLICATIONS

20+ issued and pending patents, 30+ peer-reviewed publications, and one first-author edited book (topic of Pathology AI / image analysis in drug development). Full List available upon request.